tradingkey.logo

Genfit SA

GNFT

4.260USD

+0.035+0.83%
Fechamento 09/18, 16:00ETCotações atrasadas em 15 min
212.98MValor de mercado
--P/L TTM
Mais detalhes de Genfit SA Empresa
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Informações da empresa
Código da empresaGNFT
Nome da EmpresaGenfit SA
Data de listagemDec 19, 2006
CEOMr. Pascal Prigent
Número de funcionários180
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 19
EndereçoParc Eurasante 885 avenue Eugene Avinee
CidadeLOOS
Bolsa de valoresEuronext Paris
PaísFrance
Código postal59120
Telefone33320164000
Sitehttps://www.genfit.fr/
Código da empresaGNFT
Data de listagemDec 19, 2006
CEOMr. Pascal Prigent
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Dr. Carol Addy, M.D.
Dr. Carol Addy, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mr. John Brozek
Mr. John Brozek
Executive Vice President - Data and Information Technology
Executive Vice President - Data and Information Technology
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Dr. Carol Addy, M.D.
Dr. Carol Addy, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Morgan Stanley & Co. International Plc
0.05%
AllianceBernstein L.P.
0.04%
Citadel Advisors LLC
0.04%
Outro
99.86%
Investidores
Investidores
Proporção
Morgan Stanley & Co. International Plc
0.05%
AllianceBernstein L.P.
0.04%
Citadel Advisors LLC
0.04%
Outro
99.86%
Tipos de investidores
Investidores
Proporção
Research Firm
0.05%
Investment Advisor/Hedge Fund
0.05%
Hedge Fund
0.04%
Investment Advisor
0.02%
Outro
99.84%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
22
234.11K
0.47%
-547.30K
2025Q1
25
259.00K
0.52%
-1.29M
2024Q4
26
260.49K
0.52%
-1.21M
2024Q3
28
127.35K
0.26%
-1.36M
2024Q2
31
97.15K
0.20%
-1.36M
2024Q1
31
97.93K
0.20%
-1.42M
2023Q4
31
648.17K
1.30%
-1.34M
2023Q3
32
1.16M
2.33%
-1.43M
2023Q2
30
1.77M
3.54%
-496.41K
2023Q1
30
2.19M
4.39%
-60.89K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Morgan Stanley & Co. International Plc
25.52K
0.05%
-9.20K
-26.50%
Mar 31, 2025
AllianceBernstein L.P.
22.36K
0.04%
+13.38K
+148.94%
Jun 30, 2024
Citadel Advisors LLC
12.33K
0.02%
+12.33K
--
Mar 31, 2025
Optiver Holding B.V.
13.15K
0.03%
+12.89K
+4845.49%
Mar 31, 2025
UBS Financial Services, Inc.
3.12K
0.01%
+70.00
+2.30%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.21K
0.01%
--
--
May 31, 2025
Osaic Holdings, Inc.
--
0%
-250.00
-100.00%
Mar 31, 2025
Qube Research & Technologies Ltd
--
0%
-98.00
-100.00%
Sep 30, 2024
BofA Global Research (US)
17.00
0%
+17.00
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI